GCP
EVLO

GSA Capital Partners’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

GSA Capital Partners’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,644
Closed -$247K – 1933
2022
Q1 		$247K Buy
+3,644
New +$303K 0.03% 1036
2021
Q4 		– Sell
-581
Closed -$82K – 1919
2021
Q3 		$82K Buy
+581
New +$115K 0.01% 1336

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's EVLO Position: Q2 2022 in Review

GSA Capital Partners sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 3,644 shares — an estimated $247K sold.

GSA Capital Partners first reported a position in EVLO in Q3 2021 and held it in 2 quarters. The position peaked at $247K in Q1 2022. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • GSA Capital Partners reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • GSA Capital Partners sold 3,644 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $247K.
  • GSA Capital Partners first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • GSA Capital Partners's Evelo Biosciences, Inc. Common Stock position peaked at $247K in Q1 2022.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.